Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.61 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.61 |
| ▸ | MEN1 | O00255 | 1/20 | 0.61 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | HPGD | P15428 | 2/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.58 |
| ▸ | ATM | Q13315 | 1/20 | 0.58 |
| ▸ | LMNA | P02545 | 1/20 | 0.58 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 1/20 | 0.56 |
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.56 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.56 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.54 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.53 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | CES2 | O00748 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5181766 | 0.84 | HPGD (0.66) | HDAC8HDAC6MEN1KMT2AGAA | |
| SCHEMBL60235 | 0.83 | MEN1 (0.65) | HDAC8HDAC6MEN1KMT2AGAA | |
| SCHEMBL11034177 | 0.83 | HDAC8 (0.65) | HDAC8HDAC6MEN1KMT2AGAA | |
| SCHEMBL23723912 | 0.82 | ALDH1A1 (0.43) | HDAC8HDAC6MEN1KMT2AGAA | |
| SCHEMBL9645345 | 0.82 | CA2 (0.52) | HPGDALDH1A1LMNARAB9ATRPV1 | |
| Phenaceturic Acid SCHEMBL28124919 | 0.81 | ATM (0.56) | HDAC8HDAC6MEN1KMT2AGAA | |
| SCHEMBL4683120 | 0.81 | HPGD (0.72) | HDAC8HDAC6MEN1KMT2AGAA | |
| SCHEMBL392625 | 0.81 | ALDH1A1 (0.82) | HDAC8HDAC6MEN1KMT2AGAA | |
| SCHEMBL1454495 | 0.81 | MEN1 (0.63) | HDAC8HDAC6MEN1KMT2AGAA | |
| SCHEMBL5196581 | 0.80 | HDAC2 (0.63) | HDAC8HDAC6MEN1KMT2AHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1347406-A | Carbamic acid derivs. and their use as metabotropic glutamate receptor ligands | HOFFMANN LA ROCHE (CH) | 2002-05-01 | — | — | CN | claimed |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-20120020920-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-01-26 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| EP-2206715-A1 | Fused heterotetracyclic compounds and use thereof as hcv polymerase inhibitor | Japan Tobacco, Inc. (JP) | 2010-07-14 | — | — | EP | disclosed |
| US-7659263-B2 | Thienopyrrole compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2010-02-09 | — | — | US | disclosed |
| EP-1719773-B1 | FUSED HETEROTETRACYCLIC COMPOUNDS AND USE TEHREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC (JP) | 2009-04-15 | — | — | EP | disclosed |
| US-20090036444-A1 | 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2009-02-05 | — | — | US | disclosed |
| EP-0945448-B1 | 5-ALKOXY-2(3H)-OXAZOLONE COMPOUNDS AND PROCESS FOR THE PREPARATION THEREOF | UBE INDUSTRIES (JP) | 2008-11-26 | — | — | EP | disclosed |
| US-7427616-B2 | Condensed pyridines and pyrimidines with tie2 (TEK) activity | ASTRAZENECA AB (SE) | 2008-09-23 | — | — | US | disclosed |
| EP-1000937-A1 | PROCESS FOR PRODUCING 4-ALKOXYCARBONYL-2-OXAZOLIDINONE COMPOUNDS | UBE INDUSTRIES LIMITED (JP) | 2000-05-17 | — | — | EP | disclosed |
| US-6020496-A | 5-alkoxy-2(3H)-oxazolone compounds and process for preparing the same | UBE INDUSTRIES, LTD. (JP) | 2000-02-01 | — | — | US | disclosed |
| EP-0945448-A1 | 5-ALKOXY-2(3H)-OXAZOLONE COMPOUNDS AND PROCESS FOR THE PREPARATION THEREOF | UBE INDUSTRIES, LTD. (JP) | 1999-09-29 | — | — | EP | disclosed |
| EP-0640102-A1 | ACTIVATION-STATE-SPECIFIC PHOSPHOPROTEIN IMMUNODETECTION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 1995-03-01 | — | — | EP | disclosed |
| WO-1993021230-A1 | ACTIVATION-STATE-SPECIFIC PHOSPHOPROTEIN IMMUNODETECTION | DANA-FARBER CANCER INSTITUTE, INC. (US) | 1993-10-28 | — | — | WO | disclosed |
| CN-1030917-A | IMMUNOSUPPRESSANT PEPTIDES | MERRELL DOW PHARMA (US) | 1989-02-08 | — | — | CN | disclosed |
| EP-0154190-A1 | Pyridones | MERCK PATENT GmbH (DE) | 1985-09-11 | — | — | EP | disclosed |
| US-4410530-A | CARDIO-SELECTIVE B-RECEPTOR BLOCKING AGENTS AND STIMULANTS | CIBA-GEIGY CORPORATION (US) | 1983-10-18 | — | — | US | disclosed |
| US-4195090-A | ADRENERGIC BLOCKING AGENTS | CIBA-GEIGY CORPORATION (US) | 1980-03-25 | — | — | US | disclosed |
| US-4115575-A | CARDIOVASCULAR DISORDERS | CIBA-GEIGY CORPORATION (US) | 1978-09-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036444-A1 | 5-5-Membered fused heterocyclic compound and use thereof as HCV polymerase inhibitor | GTF3C5, ZC3HAV1, POLI | HDAC8 432/4885HDAC6 64/4885MEN1 4807/4885 |
| US-20120020920-A1 | 5-5-MEMBERED FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | GTF3C5, ZC3HAV1, POLI | HDAC8 432/4885HDAC6 64/4885MEN1 4807/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | HDAC8 380/4885HDAC6 82/4885MEN1 4753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.